Lunai Bioworks Inc. FY 2026: Revenue $52K, Net loss $(3.56M), EPS $(1.06) — 10-K Summary

Lunai Bioworks Inc. reported FY 2026 revenue of $52K, a net loss of $3.56M, and EPS of $(1.06), improving from FY 2025. The company shifted focus to AI-driven precision medicine, reduced costs, and acquired IP to accelerate R&D. Programs remain preclinical, and additional financing is being pursued.

Original reporting
Published Oct 13, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lunai Bioworks Inc. FY 2026: Revenue $52K, Net loss $(3.56M), EPS $(1.06) — 10-K Summary — source image
Decision brief

The 30-second read

$LNAINeutralLow
01

Why it matters

For traders, the key takeaway is the combination of minimal revenue scale and improved losses, plus ongoing preclinical-stage programs and an implied need for future funding.

02

Market read

The filing can influence microcap biotech sentiment, but the text lacks a new financing deal, regulatory decision, or clinical readout that would drive a high-conviction near-term trade.

03

What to watch

The article flags pursuit of additional financing but provides no amount or runway; that omission can dominate near-term risk pricing for microcaps.

Relevance 4/10Novelty 4/10Timing: 10-K summary published after market close, useful for positioning ahead of follow-on financing or development updates.

Background

The piece summarizes Lunai Bioworks’ FY2026 10-K results, including a shift toward AI-driven precision medicine and therapeutics.

Company-level read

Ticker impact

$LNAINeutralMedium confidence
Context

Lunai Bioworks reports FY2026 revenue of $51,992 and diluted EPS loss of $(1.06), plus a narrowed net loss versus FY2025.

Expected impact

Likely modest relief bid on loss narrowing, offset by concerns about minimal revenue and preclinical-stage execution risk.

Evidence & confidence

The article provides concrete FY2026 financials and business updates, but it is a 10-K summary with no explicit guidance, financing terms, or immediate catalyst beyond the filing.

Market effects

Highlights typical biotech AI-therapeutics execution risk, where revenue remains service-like and product revenue depends on future regulatory approvals.

No clear regional market linkage beyond US microcap biotech sentiment.

Limited, as the disclosure is company-specific and not tied to global regulatory or clinical milestones in the text.

Counterpoint

Loss narrowing may reflect prior-year one-offs or cost timing, so investors may discount it if cash burn and financing needs are not addressed with new terms.

Key entities

  • Lunai Bioworks Inc.

    US-listed biotech company reporting FY2026 revenue of $51,992 and diluted EPS loss of $(1.06), with a strategic pivot to AI-driven precision medicine.

Related articles

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$RRGBMedAI 8/10

RED ROBIN GOURMET BURGERS, INC. REPORTS THIRD QUARTER OF FISCAL 2026 RESULTS

RED ROBIN GOURMET BURGERS INC (RRGB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RED ROBIN GOURMET BURGERS, INC. REPORTS THIRD QUARTER OF FISCAL 2026 RESULTS Englewood, CO – November 18, 2026 – Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) ("Red Robin" or the "Company"), a casual dining restaurant chain serving an innovative selection of high-qu